ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 297 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q3 2021. The put-call ratio across all filers is 0.67 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $26,618,174 | -27.9% | 990,628 | -4.3% | 0.01% | -25.0% |
| Q2 2023 | $36,910,383 | +39.7% | 1,035,064 | -0.5% | 0.01% | +33.3% |
| Q1 2023 | $26,415,822 | -39.0% | 1,039,993 | -2.5% | 0.01% | -40.0% |
| Q4 2022 | $43,281,941 | +22.0% | 1,067,109 | -0.6% | 0.01% | +11.1% |
| Q3 2022 | $35,491,000 | -2.8% | 1,073,815 | +3.6% | 0.01% | +12.5% |
| Q2 2022 | $36,496,000 | -24.0% | 1,036,572 | -0.8% | 0.01% | -11.1% |
| Q1 2022 | $48,047,000 | -30.6% | 1,044,740 | +0.1% | 0.01% | -25.0% |
| Q4 2021 | $69,201,000 | +4.6% | 1,043,751 | -1.5% | 0.01% | -7.7% |
| Q3 2021 | $66,140,000 | -26.4% | 1,059,433 | -2.4% | 0.01% | -23.5% |
| Q2 2021 | $89,899,000 | +33.5% | 1,085,471 | +6.9% | 0.02% | +21.4% |
| Q1 2021 | $67,348,000 | -15.4% | 1,015,636 | -2.1% | 0.01% | -17.6% |
| Q4 2020 | $79,573,000 | +74.2% | 1,037,071 | -2.2% | 0.02% | +54.5% |
| Q3 2020 | $45,672,000 | -3.5% | 1,060,671 | -3.2% | 0.01% | -15.4% |
| Q2 2020 | $47,349,000 | +54.4% | 1,096,297 | +2.9% | 0.01% | +30.0% |
| Q1 2020 | $30,658,000 | -54.5% | 1,065,598 | +0.3% | 0.01% | -41.2% |
| Q4 2019 | $67,415,000 | +118.0% | 1,062,801 | -3.1% | 0.02% | +112.5% |
| Q3 2019 | $30,923,000 | +9.7% | 1,097,359 | +3.1% | 0.01% | 0.0% |
| Q2 2019 | $28,193,000 | +310.5% | 1,063,856 | +184.3% | 0.01% | +300.0% |
| Q1 2019 | $6,868,000 | +54.5% | 374,264 | +4.6% | 0.00% | +100.0% |
| Q4 2018 | $4,445,000 | -46.0% | 357,920 | -16.7% | 0.00% | -50.0% |
| Q3 2018 | $8,239,000 | +78.0% | 429,780 | +26.3% | 0.00% | +100.0% |
| Q2 2018 | $4,628,000 | +733.9% | 340,244 | +341.7% | 0.00% | – |
| Q1 2018 | $555,000 | +152.3% | 77,039 | +29.1% | 0.00% | – |
| Q4 2017 | $220,000 | -23.1% | 59,664 | -9.7% | 0.00% | – |
| Q3 2017 | $286,000 | +153.1% | 66,065 | -5.2% | 0.00% | – |
| Q2 2017 | $113,000 | -80.6% | 69,664 | -77.8% | 0.00% | – |
| Q1 2017 | $581,000 | +23.6% | 314,034 | +3.7% | 0.00% | – |
| Q4 2016 | $470,000 | -78.2% | 302,935 | +3.2% | 0.00% | -100.0% |
| Q3 2016 | $2,157,000 | +39.4% | 293,450 | +1.0% | 0.00% | – |
| Q2 2016 | $1,547,000 | – | 290,559 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
| Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
| L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
| First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
| ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
| Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
| Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
| Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
| Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |